1. Fifteen new antidepressants were approved by the FDA between 2009 and early 2025, with 18 additional drugs in Phase 3 development for major depressive disorder.
2. The review highlights a shift beyond monoaminergic mechanisms, with several agents targeting NMDA, GABA-A, and kappa-opioid receptors.
3. All newly approved oral antidepressants were formulated for once-daily dosing to enhance adherence.
4. The analysis highlights ongoing efforts to address treatment-resistant depression, affecting an estimated 30% of patients.
5. Findings suggest a diversifying therapeutic landscape, offering new pharmacologic options for patients inadequately managed by traditional SSRIs and SNRIs.

Source: BMC Psychiatry